1 / 69

Hepatitis A, B, C, D, E, G,… diagnostic tools and their use

Hepatitis A, B, C, D, E, G,… diagnostic tools and their use . Geert Leroux-Roels Laboratorium voor Klinische Biologie UZ Gent. Human Hepatitis Viruses Discovery and characteristics. Human Hepatitis Viruses Diagnostic tools. Epidemiology of HAV. Hepatitis A virus – diagnostic tools.

yoland
Download Presentation

Hepatitis A, B, C, D, E, G,… diagnostic tools and their use

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Hepatitis A, B, C, D, E, G,…diagnostic tools and their use Geert Leroux-Roels Laboratorium voor Klinische Biologie UZ Gent

  2. Human Hepatitis VirusesDiscovery and characteristics

  3. Human Hepatitis VirusesDiagnostic tools

  4. Epidemiology of HAV

  5. Hepatitis A virus – diagnostic tools • Serology • Anti-HAV IgM acute HAV infection • Anti-HAV Totaal immunity - natural - vaccine-induced protective level 10-30 IU/L • HAV detection in blood and blood products in faeces, saliva, … in shelfish, food products in water,sewage,

  6. HAV vaccines • Children (2-15) Havrix Junior (720 U/dose), 0.5 ml ml/d scheme : 0 and 6-12 mo (2 doses, IM) • Adults (>15) Havrix 1440 (1440 U/dose, 1 ml/d scheme : 0 and 6-12 mo (2 doses, IM)

  7. Epidemiology of HEVepidemische en sporadische gevallen Rare cases in western countries after recent travel in endemic area

  8. Hepatitis E virus Serology anti-HEV IgM anti-HEV IgG HEV-RNA

  9. Hepatitis B virus Diagnostic tools and interpretation

  10. HBV: genome and gene products • 3200 baseparen • 4 open reading frames • 7 proteins • large (preS1-preS2-S) • Middle (preS2-S) • Small or HBsAg • nucleocapsid or HBcAg • secreted HBe-Ag • Polymerase • X protein

  11. Inflammation and liver cell damage Transaminases ALT/AST en other biochemical markers Antigens Antibodies HBsAganti-HBs HBcAg anti-HBc-Tot anti-HBc-IgM HBeAg anti-HBe • Detection/quantific. • of HBV DNA • Commercial assays • Branched DNA (Bayer) • PCR (Roche Amplicor) • In-house nested PCR • In-house real-time PCR Diagnostic markers of HBV infection

  12. Usefulnessof HBV-DNA quantification • Diagnosis • Acute HBV infection : HBV DNA is not useful • Chronic HBV infection – Is HBV replicating ? • HBeAgpos : not useful • HBeAgneg/anti-HBepos : useful, “threshold value” ? • Prognosis • Therapy • Decision to treat : ALT, biopsy, HBeAgpos • Selection treatment • Monitoring : HBV DNA, ALT, HBeAg, anti-HBe,

  13. Evolution of an acute, self-limited HBV infection

  14. Serologic profile of a chronic HBV infection, with a late seroconversion to anti-HBe

  15. Case 1 • 41 years old Afghan male • political refugee • In training for assistant-cook • Medical screening exam for ‘hepatitis’ • No symptoms • No history of hepatitis

  16. Results - blood chemistry

  17. Question 1 Can HBsAg and anti-HBs occur concomitantly ? Results - serology

  18. [HBsAg-anti-HBs] immune complexes • Are present during the clearance phase of an acute HBV infection in the “window phase” and in some chronic HBV patients • Routine tests for HBsAg/anti-HBs do not detect immune complexes (IC) • IC dissociatie (ICD) by treatment of serum (100µl) with HCl (50 µl, 0.5 N, 1h at 37°C) and neutralisation with NaOH (50 µl, 0.5N)(Rabenau et al. 1996) • Research tests can detect IC’s

  19. HAV serostatus • anti-HAV-IgM antibodies are only present in the acute phase of HAV infections • ALT/AST activities are normal • Anti-HAV status (IgG antibodies) would have been useful to see whether this person still needs HAV vaccination • Food handling • Chronic HBV infection

  20. Question 2 Is this person infectious ??? Question 3 Does he need treatment ? Results – additional HBV tests

  21. Infectivity is LOW • Spouse and daughter show no signs or markers of HBV infection (HBsAlneg) • Vaccination of household (sexual contact) ! • Twinrix is an alternative for Engerix-B • Therapy is not indicated • Normal transaminases, low DNA • Follow-up : annually ?

  22. Case 2 • Man, born in 1947 • 1986 – Ulcerative colitis • 1992 - liver enzymes slightly elevated, no further investigations • 1998 – abnormal liver tests, alcohol consumption, • June 1998 – exacerbation of colitis • Nov 2001 - exacerbation of colitis

  23. Evolution of laboratory tests

  24. Spontaneous seroconversions in chronic HBV • HBeAg to anti-HBe seroconversion • Inflammation (ALT/AST) = 8-15% per year • Normal ALT <2% in children < 3 years 4-5% in patients > 3 years • HBsAg to anti-HBs seroconversion • Active HBeAg- hepatitis 0.5% /jaar • Asymptomatic HBeAg- carrier • In a western population 1-2% /jaar • Post perinatal infection 0.05-0.8% /jaar

  25. HBeAg/anti-HBe seroconversion • Transition to ‘inactive carrier’ • Normalisation of transaminases • Low viral replication and HBV DNA (<105 gEq/ml) • Active hepatitis with HBeAg-/anti-HBe+ • Elevated transaminases • High(er) HBV DNA (> 105 gEq/ml) • Precore mutation (G1896A: stop codon) • Core/precore promotor mutations

  26. -29 aa 183 aa 1 HBeAg precursor P G1896A aa -10 aa 1 aa 149 AUG AUG mature HBeAg aa 183 aa 1 HBcAg Hepatitis B core and e antigen

  27. Interpretation of the serology and its evolution in this patient (case 2) • Spontaneous seroconversion of HBsAg to anti-HBs • No detectable [HBsAg-anti-HBs] IC’s • HBV DNA detection, quantification and sequence analysis are needed for a correct diagnosis and prognosis

  28. Case 3 • Man, 45 years • Traffic accident => brain death • Possible organ donor (liver ?) • Serology : • HBsAgneg, anti-HBsneg,anti-HBcpos, anti-HCVneg,anti-HIVneg, CMVneg • Biochemistry : no abnormalities

  29. Prevalence of “anti-HBc alone” in low seroprevalence populations

  30. Prevalence of “anti-HBc alone” in high seroprevalence populations

  31. 1 2 1 = window phase 2 = late immunity, only anti-HBc persists 3 3 = chronic infection with low replication/production of HBV or with HBsAg mutant Possible causes of “Anti-HBc alone” serology

  32. “Occult hepatitis” • Typical serology HBsAgneg, anti-HBsneg, anti-HBcpos • HBV DNA < detection limit of routine PCR test (e.g. < 200 gEq/mL) • HBV DNA in the liver

  33. Influence of HCV infection on HBV replication • HCV core protein suppresses HBV replication with a factor 2 to 4 • HCV infection reduces the expression of HBsAg in the liver • Treatment of HCV with IFNaalsohas an effect on HBV

  34. “anti-HBc alone” can be : • Window phase • Late immunity – only sign of past infection • Chronic infection – “occult infection” • HBsAg mutant • “False” positive test result • really “false positive” – low signal, 2nd EIA • Core-binding antibodies (IgM vs IgG)

  35. HBV Replication Host Imm Resp Liver Disease ALT = Hi Hi = to Hi = to Hi = HBsAg ++ ++ ++ + - + Anti-HBc + + + + + + HBeAg + + - - - - Anti-HBe - - + + + or - + or - HBV DNA Hi PCR Hi PCR Hi PCR Lo PCR Nested PCR - Active Hepatitis Tolerance HBeAg+ HBeAg- Occult Inactive carrier mutant serocon

  36. Lab Tools IgM anti-HDV HDV-Ag anti-HDV HDV-RNA

  37. Hepatitis C virus Diagnostic tools and interpretation

  38. The HCV genome and expressed polyprotein

  39. Markers of HCV infection • Indirect markers • anti-HCV • ELISA 3-4th generation • Confirmation tests RIBA, LIA • Direct markers = HCV genome • RT-PCR qualitative and quantitative • Branched-DNA (quantitative) • Genotyping • HCV core antigen

  40. Anti-HCV assays: generations 1 to 4 1989 1993 2000 Generation 1 2 3 4 Antigens NS3/4 C,NS3,NS4 C,NS3,NS4A/B,NS5A Sensitivity 95-98% >99% Specificity <95% 99.8% Lag time (wks) 16-24 4-12 4-8

  41. Confirmation of anti-HCV+ • Repeat ELISA on the same sample • Another ELISA on the same sample • Same ELISA on a new sample • Confirmation assays • RIBA (recombinant immunoblot assay) • LIA (Line immuno assay) • Confirmation by PCR

  42. Molecular tests for HCV • Molecular detection – qualitative • Molecular quantification • Genotyping

  43. HCV-RNA detection – qualitative

  44. Qualitative HCV-RNA tests • Confirms diagnosis of HCV infection • Useful for the early diagnosis of acute hepatitis C • Demonstrates the presence of active infection • « Gold standard » for documenting response to therapy

  45. Interpretation of combined anti-HCV and HCV-RNA results

  46. Treatment of HCV • Clinical studies evaluating the efficacy of different treatment protocols : drugs, doses, duration, … have revealed the importance of 1) HCV-RNA quantification 2) genotyping

More Related